Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST

Fineline Cube Jul 9, 2026
Company Deals

Xenovector and Jilin University Launch Strategic Partnership to Advance Gene-Edited Pig Organ Transplantation from Breakthrough to Affordable Healthcare

Fineline Cube Jul 9, 2026
Company Deals

Zhejiang Hisun Pharmaceutical and Tigermed Forge Strategic Alliance to Create End-to-End Innovative Drug Development Pipeline

Fineline Cube Jul 9, 2026
Company Deals

Transcenta Returns Select Lilly Assets in Portfolio Restructuring, Retains Blosozumab Rights

Fineline Cube Jul 8, 2026
Company Deals Digital

Hanx Biopharmaceuticals Partners with HUST-CityU Macau Institute to Establish AI-Driven Drug Discovery Joint Laboratory

Fineline Cube Jul 8, 2026
Policy / Regulatory

China’s National Health Commission Unveils 2026 Essential Medicines List, Adding 116 New Drugs with Full Insurance Coverage

Fineline Cube Jul 9, 2026
Company Drug

Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients

Fineline Cube Jul 9, 2026
Company Drug

Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs

Fineline Cube Jul 9, 2026
Company Drug

Triastek’s T22 Gastric Retention Capsules Gain NMPA IND Clearance

Fineline Cube May 22, 2025

Nanjing-based Triastek Inc., a pioneer in 3D-printed pharmaceutical formulations, has obtained Investigational New Drug (IND)...

Company Drug

Boehringer Ingelheim’s Metalyse Approved in China for Acute Ischemic Stroke

Fineline Cube May 22, 2025

Germany-based pharmaceutical leader Boehringer Ingelheim announced receiving marketing approval from China’s National Medical Products Administration...

Company

Well Lead Medical to Set Up Subsidiary and Manufacturing Base in Indonesia

Fineline Cube May 22, 2025

Guangzhou-based medical catheter specialist Well Lead Medical Co., Ltd (SHA: 603309) plans to establish a...

Company Drug

Kelun-Biotech’s Sacituzumab Tirumotecan Accepted for NMPA Review for HR+, HER2- Breast Cancer

Fineline Cube May 22, 2025

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) announced that another indication approval filing for its...

Company Deals

Shandong Buchang Pharmaceuticals Partners with FBC for MF59 Adjuvant R&D

Fineline Cube May 22, 2025

China-based Shandong Buchang Pharmaceuticals Co., Ltd (SHA: 603858) announced plans to enter into an Entrusted...

Policy / Regulatory

HHS Implements Trump’s Order for Most-Favored-Nation Drug Pricing

Fineline Cube May 22, 2025

The U.S. Department of Health and Human Services (HHS) announced that it is taking immediate...

Company Drug

Nuance Pharma’s Ohtuvayre Meets Primary Endpoints in COPD Study

Fineline Cube May 22, 2025

China-based Nuance Pharma announced positive topline results from the ENHANCE-CHINA study (NCT05743075) for its nebulized...

Company Drug

AccurEdit Therapeutics’ ART001 Receives FDA RMAT Designation for ATTR

Fineline Cube May 22, 2025

China-based gene editing therapy specialist AccurEdit Therapeutics (Suzhou) Co., Ltd announced receiving Regenerative Medicine Advanced...

Company Deals

AstraZeneca Completes Acquisition of EsoBiotec for Up to USD 1 Billion

Fineline Cube May 22, 2025

UK-based major AstraZeneca (AZ; NASDAQ: AZN) announced the completion of its acquisition of EsoBiotec SA,...

Company Deals

Pulnovo Medical Raises Tens of Millions in New Financing Round

Fineline Cube May 21, 2025

Wuxi-based Pulnovo Medical Limited, a developer of medical devices for hypertension and heart failure, announced...

Company Deals Medical Device

PHASE Scientific Completes Series A Financing to Advance Urine-Based Diagnostics

Fineline Cube May 21, 2025

Hong Kong-based urine-based diagnostics specialist PHASE Scientific International Limited announced the completion of a Series...

Policy / Regulatory

China’s CDE Announces 94th Batch of Reference Preparations for Generic Evaluation

Fineline Cube May 21, 2025

China’s Center for Drug Evaluation (CDE) has selected the 94th batch of reference preparations for...

Company Deals

Merck KGaA Partners with IMEC to Develop Advanced Microphysiological Systems Platform

Fineline Cube May 21, 2025

German major Merck KGaA (ETR: MRK) this week announced a partnership with Belgium-based Interuniversity Microelectronics Centre...

Company Deals Drug

Antengene and MSD Collaborate on ATG-022 for Advanced Solid Tumors

Fineline Cube May 21, 2025

China-based Antengene Corporation Limited (HKG: 6996) has entered into a collaboration with US major Merck,...

Hospital Policy / Regulatory

China’s County Hospitals Show Improved Medical Service Capability in 2024

Fineline Cube May 21, 2025

The National Health Commission (NHC) released a notice reporting the status of the county hospital...

Company Drug

3SBio Registers Phase III Study for SSGJ-707 in Advanced NSCLC

Fineline Cube May 21, 2025

China-based 3SBio Inc. (HKG: 1530) announced this week the registration of the first Phase III...

Company Drug

Ascletis Pharma Initiates ASC47-103 Study in US for Obesity Treatment

Fineline Cube May 21, 2025

China-based Ascletis Pharma Inc. (HKG: 1672) announced the first subject dosing of the ASC47-103 study...

Company Deals

Yifan Pharma Licenses Ryzneuta to Lenis for Balkan Markets

Fineline Cube May 21, 2025

China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) announced a licensing agreement with Lenis, a Slovenian-based...

Company Drug

Abbisko’s Pimitinib Granted Priority Review for TGCT Treatment in China

Fineline Cube May 21, 2025

Abbisko Therapeutics Co., Ltd (HKG: 2256) announced that its self-developed, highly selective small-molecule CSF-1R inhibitor,...

Company Drug

Minghui Pharmaceutical Launches Phase II Study of Combination Therapy for Advanced NSCLC

Fineline Cube May 21, 2025

China-based Minghui Pharmaceutical Inc. announced the initiation of a Phase II clinical study to evaluate...

Posts pagination

1 … 185 186 187 … 693

Recent updates

  • Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients
  • Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs
  • Shenyang Xingqi Pharmaceutical Reports Positive Phase 2 Results for SQ-22031 Eye Drops in Neurotrophic Keratitis, Advances to Pivotal Phase 3 Trial
  • Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST
  • Changchun High & New Technology’s Subsidiary GenSci Secures NMPA IND Acceptance for GenSci148, First-in-Class VEGF Multi-Blocker for Retinal Vascular Diseases
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients

Company Drug

Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs

Company Drug

Shenyang Xingqi Pharmaceutical Reports Positive Phase 2 Results for SQ-22031 Eye Drops in Neurotrophic Keratitis, Advances to Pivotal Phase 3 Trial

Company Deals

Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.